20.500.12556/DKUM-96035 Vpliv zaviralcev imunskih nadzornih točk in kemoterapije na preživetje in kakovost življenja pacientov z napredovalim nedrobnoceličnim pljučnim rakom The impact of immune checkpoint inhibitors and chemotherapy on survival and quality of life in patients with advanced non-small cell lung cancer Uvod: Nedrobnocelični rak pljuč (NDRP) predstavlja približno 85 % pljučnih rakov, prognoza napredovale bolezni pa ostaja slaba. Namen zaključnega dela je bil raziskati, kako zdravljenje z zaviralci imunskih nadzornih točk (ZINT) v primerjavi z zdravljenjem s kemoterapijo v prvi liniji zdravljenja vpliva na preživetje pacientov z napredovalim NDRP in njihovo kakovost življenja. Metode: Uporabili smo deskriptivno metodo dela ter izvedli sistematični pregled strokovne in znanstvene literature v podatkovnih bazah CINAHL Ultimate (EBSCOhost), Cochrane Library in PubMed ter dodatno v referencah v pregledanih člankih. Kritično oceno raziskav smo izvedli z orodjem CASP, splošno oceno kakovosti pa MERGE, sintezo pa z opisno metodo. Rezultati: V končno analizi smo vključili 14 raziskav, 9 sistematičnih pregledov z metaanalizo in 5 randomiziranih kliničnih raziskav faze III. Rezultati kažejo, da zdravljenje z ZINT v prvi liniji zdravljenja pomembno podaljša celokupno preživetje in preživetje brez napredovanja bolezni v primerjavi s kemoterapijo. Večina raziskav poroča tudi o boljši ali vsaj ohranjeni kakovosti življenja pri pacientih, zdravljenih z ZINT. Razprava in zaključek: ZINT v primerjavi s kemoterapijo pomembno izboljšajo preživetje in kakovost življenja pacientov z napredovalim NDRP. Potrebne so nadaljnje raziskave dolgoročnih učinkov in obvladovanja imunsko pogojenih neželenih učinkov. Introduction: Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, and the prognosis of advanced disease remains poor. The aim of this thesis was to investigate how treatment with immune checkpoint inhibitors (ICIs), compared to chemotherapy as first-line therapy, affects the survival and quality of life of patients with advanced NSCLC. Methods: We used a descriptive research method and conducted a systematic review of professional and scientific literature in the databases CINAHL Ultimate (EBSCOhost), Cochrane Library, and PubMed, as well as additional references found in the reviewed articles. The critical appraisal of the studies was carried out with the CASP tool, the overall quality assessment with MERGE, and the synthesis was descriptive. Results: The final analysis included 14 studies, comprising nine systematic reviews with meta-analyses and five phase III randomized controlled trials. First-line treatment with ICIs significantly prolonged overall survival and progression-free survival compared to chemotherapy. Most studies reported improved or at least maintained quality of life in patients treated with ICIs. Discussion and conclusion: Compared to chemotherapy, ICIs significantly improve survival and quality of life in patients with advanced NSCLC. Further research is needed to evaluate long-term effects and to optimize the management of immune-related adverse events. zaviralci imunskih nadzornih točk kemoterapija napredovali nedrobnocelični rak pljuč kakovost življenja preživetje check point inhibitors chemotherapy advanced non-small cell lung cancer quality of life survival true false false [N. Koser] Slovenski jezik Angleški jezik Magistrsko delo/naloga 2025-11-25 06:21:42 2026-01-12 08:53:02 2026-01-13 03:17:15 0000-00-00 00:00:00 2025 0 Maribor 0 0000-00-00 NiDoloceno NiDoloceno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 612.017:616.277:616.24-006-052(043.2) 262579459 MAG_Koser_Natasa_2025.pdf MAG_Koser_Natasa_2025.pdf 1 DF11EAC9E2A5876F2A6D0D5C48F90237 e892761af04854217d40aaf5d7f07acf6afac28cdf0abbbd8caab6a2c4a28788 b74dbb0a-c9bf-11f0-8fc7-00155d000105 https://dk.um.si/Dokument.php?lang=slv&id=200871 Fakulteta za zdravstvene vede 0 0 0